CN102327230B - Protein nanometer granules wrapped with taxane medicaments and preparation method for nanometer granules - Google Patents
Protein nanometer granules wrapped with taxane medicaments and preparation method for nanometer granules Download PDFInfo
- Publication number
- CN102327230B CN102327230B CN201110299784.9A CN201110299784A CN102327230B CN 102327230 B CN102327230 B CN 102327230B CN 201110299784 A CN201110299784 A CN 201110299784A CN 102327230 B CN102327230 B CN 102327230B
- Authority
- CN
- China
- Prior art keywords
- preparation
- protein
- taxone
- water
- nano granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 103
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 92
- 239000008187 granular material Substances 0.000 title claims abstract description 80
- 239000003814 drug Substances 0.000 title abstract description 94
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract description 6
- 229940123237 Taxane Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 64
- 239000000725 suspension Substances 0.000 claims abstract description 31
- 239000000126 substance Substances 0.000 claims abstract description 27
- 239000003960 organic solvent Substances 0.000 claims abstract description 23
- 239000007962 solid dispersion Substances 0.000 claims abstract description 21
- 239000012876 carrier material Substances 0.000 claims abstract description 15
- 239000012736 aqueous medium Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 235000018102 proteins Nutrition 0.000 claims description 97
- 229960001592 paclitaxel Drugs 0.000 claims description 89
- 229930012538 Paclitaxel Natural products 0.000 claims description 82
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 82
- 102000009027 Albumins Human genes 0.000 claims description 71
- 108010088751 Albumins Proteins 0.000 claims description 71
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- 239000000243 solution Substances 0.000 claims description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 23
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 238000007500 overflow downdraw method Methods 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- -1 aliphatic ester Chemical class 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 15
- 229960003668 docetaxel Drugs 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 239000010695 polyglycol Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 239000004367 Lipase Substances 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 108090001060 Lipase Proteins 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 235000019421 lipase Nutrition 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 229920000151 polyglycol Polymers 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002228 disulfide group Chemical group 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 abstract description 32
- 230000008569 process Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 description 39
- 239000000523 sample Substances 0.000 description 38
- 239000002245 particle Substances 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 30
- 239000002105 nanoparticle Substances 0.000 description 30
- 239000000843 powder Substances 0.000 description 30
- 102000008100 Human Serum Albumin Human genes 0.000 description 25
- 108091006905 Human Serum Albumin Proteins 0.000 description 25
- 238000005516 engineering process Methods 0.000 description 19
- 241000209094 Oryza Species 0.000 description 18
- 235000007164 Oryza sativa Nutrition 0.000 description 18
- 235000013339 cereals Nutrition 0.000 description 18
- 235000009566 rice Nutrition 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229960004756 ethanol Drugs 0.000 description 15
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 238000011068 loading method Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229940090044 injection Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000013019 agitation Methods 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 239000002577 cryoprotective agent Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000010494 opalescence Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 239000006069 physical mixture Substances 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000007096 poisonous effect Effects 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012412 chemical coupling Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 125000002456 taxol group Chemical group 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- YXXURDJTDAAEPH-UHFFFAOYSA-N 2-aminopropanethioic s-acid Chemical compound CC(N)C(S)=O YXXURDJTDAAEPH-UHFFFAOYSA-N 0.000 description 2
- 108010077480 Albumin Receptors Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005354 coacervation Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- VLCAYQIMSMPEBW-UHFFFAOYSA-N methyl 3-hydroxy-2-methylidenebutanoate Chemical compound COC(=O)C(=C)C(C)O VLCAYQIMSMPEBW-UHFFFAOYSA-N 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 229940108949 paclitaxel injection Drugs 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000009193 Caveolin Human genes 0.000 description 1
- 108050000084 Caveolin Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000002185 docetaxel anhydrous group Chemical group 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000004736 wide-angle X-ray diffraction Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of pharmacy, and discloses protein nanometer granules wrapped with taxane medicaments and a preparation method for the nanometer granules. In a formula, the granules comprise the following substances in percentage by weight: 0.1 to 10 percent of taxane medicaments, 0.1 to 40 percent of water-soluble carrier material and 50 to 90 percent of protein substances. The method comprises the following steps of: preparing water-soluble carrier solid dispersion containing the taxane medicaments from the taxane medicaments and the water-soluble carrier material; adding the obtained solid dispersion into an aqueous medium containing the protein substances, mixing uniformly, and performing high-shear treatment on the mixture to obtain suspension of the protein nanometer granules wrapped with slightly-soluble medicaments; and further preparing required formulations. The protein nanometer granules have the advantages of large medicine-carrying quantity, uniform grain diameters, high stability and safety and the like; and by the method, toxic organic solvent residues are avoided, the safety of clinical administration is improved, and a process is simple, low in cost and high in operability.
Description
Technical field
The invention belongs to pharmaceutical field, relate to a kind of its preparation method of the protein nano granule that wraps up taxone.
Background technology
Taxone (as paclitaxel, Docetaxel etc.) is one of effective antitumour medicine being used clinically at present.Paclitaxel is that the bark from Ramulus et folium taxi cuspidatae or its kind found of the seventies or needle, to separate the natural product Docetaxel that obtains be semi-synthetic product, finds that afterwards this is the antitumor agent that a class has special Anticancer Effect and Mechanism.
The Anticancer Effect and Mechanism of taxone is to promote microtubule polymerization, reduces the depolymerization speed of microtubule, thereby makes microtubule in stable non-functional state, thereby reach the object that stops tumor cell mitosis and propagation.And preclinical study shows that Docetaxel is compared with paclitaxel, to the affinity of microtubule is stronger, plasma half-life is longer and cell in the holdup time longer.
Although taxone has good antitumor action, but its water solublity is lower (about 10ug/ml) all, the paclitaxel injection that therefore used clinically and Docetaxol injection all need to use respectively surfactant polyoxyethylene Oleum Ricini and polyoxyethylene sorbitan monoleate (tween 80) and cosolvent ethanol to come the object of dissolving taxol drug.Paclitaxel injection and Docetaxol injection are respectively successfully to develop the product of listing by Bristol-Myers Squibb Co. of the U.S. and French Sanofi-Aventis company the earliest.
Although use surfactant polyoxyethylene Oleum Ricini and Polysorbate is after 80s can be mixed with injection, but its toxic and side effects in clinical practice is larger, easily cause more complication, comparatively common comprise the untoward reaction such as anaphylaxis, bone marrow depression (main manifestations is that neutrophilic granulocyte reduces), fluid retention, neurotoxicity, alopecia.
A large amount of polyoxyethylene castor oils that studies show that can promote a large amount of histamine releasings in vivo, and then produce anaphylaxis, also can cause nerve conduction to postpone sensory nerve pathological changes.In addition, polyoxyethylene castor oil can also form molecule encapsulation paclitaxel molecule in blood, has affected the diffusion of drug molecule to tissue, thereby has affected its Graft Versus Tumor.Also there are some researches show the divinyl hexyl phthalate (Diethylehexy Phthalate) in polyoxyethylene castor oil solubilized PVC transfusion device.And polyoxyethylene sorbitan monoleate (tween 80) has hemolytic, and viscosity is large, and clinical application is very inconvenient.All there is certain problem at aspects such as toxic and side effects, convenient drug administration and stability in above-mentioned injection formulation, therefore develops new taxone form of administration and necessitate.
The polymer of many biocompatibility can be used for preparing polymer shell, is wrapped in the outside of water-fast pharmacologically active medicine.In fact any polymer, natural or synthetic, as long as can contain sulfydryl or disulfide bond in its structure as required, just can be for surrounding's formation one deck disulfide bond crosslinking shell of water-fast pharmacologically active medicine actually.The protein that contains cysteine and/or disulfide bond is pharmaceutically acceptable biological vehicle, and this patent is take human serum albumin as example.
Human serum albumin (human serum albumin, the protein of the strand sugar based HSA) being formed by 585 aminoacid, molecular mass 66.5kDa, be rich in protein (accounting for the 50%-60% of human plasma total protein) in human plasma, there is the feature of long circulation (half-life reaches 19 days) in stable chemical performance, safety non-toxic, non-immunogenicity, good biocompatibility, biodegradable, body.
HSA, as antineoplastic drug carrier material, has lot of advantages, mainly comprises:
1. superior drug loading potentiality: on HSA polypeptide chain with more polar group and hydrophobic amino acid, small-molecule drug, particularly insoluble drug to 70% has the affinity of height, and can there is Reversible binding, for its payload and release provide possibility; In albumin secondary structure containing having an appointment 48% α-helixstructure, 15% beta-pleated sheet structure, all the other are random coil structure, therefore have a lot of netted spaces, have created favourable steric requirements for carrying medicine.
2. broad-spectrum tumor targeting: albumin is the important nitrogenous source of tumor cell, the tumor of Fast Growth has very strong picked-up and deposit albumin ability.HSA, as antineoplastic drug carrier, is combined by the Albumin receptor on endothelial cellular membrane, the caveolin on active cell film, thus antitumor drug is transferred in tumor cell interstitial.Tumor cell interstitial and tumor cell surface are rich in a large amount of aminothiopropionic acid acidic secretion albumen, this protein function is similar to Albumin receptor, can attract specially and adhere to albumin, and aminothiopropionic acid acidic secretion albumen is in all overexpressions of nearly all tumor tissues (bladder, liver, ovary, kidney, digestive tract, mammary gland etc.), this has just formed the medicine storage pond in tumor tissues, for the wide spectrum target killing of the albumin nanometer carrier of loaded with anti-tumor medicine provides may.
3. structure modifiability: contain a large amount of reaction active groups in HSA structure, as free amine group, carboxyl, sulfydryl etc., can, with antitumor drug by chemical bond coupling, improve drug solubility, improve body-internal-circulation time and tumor-targeting; Also can with antibody or part etc. " target molecule " coupling, further improve the cancer target performance of HSA nano-carrier.In recent years, also have and report macromolecular material phase couplings such as HSA and glucosan, aldohexose or PNIPAM to improve the physicochemical property of HSA as drug carrier material.
In view of HSA has unique advantage as drug carrier material, at present both at home and abroad to mainly concentrating on both direction based on albuminous drug delivery system research:
1. prodrug: utilize a large amount of reaction active groups of HSA, by medicine, especially antitumor drug (amycin, paclitaxel, Docetaxel, methotrexate, mitomycin, 5-fluorouracil) chemical coupling in free amine group, carboxyl or the sulfydryl of HSA, to improve drug solubility, to improve body-internal-circulation time and tumor-targeting, existing more report abroad.
But by by HSA and the direct chemical coupling of medicine, there is following problem: 1) medicine selectable range is narrow: medicine need have certain reaction active groups, and easily lost efficacy at chemical coupling process Chinese medicine; 2) ambiguity of curative effect performance: between medicine and HSA, the easy degree of chemical bond rupture has determined the performance of curative effect of medication, too fast fracture, HSA loses the advantage as carrier material, crosses fracture slowly, and medicine cannot be brought into play curative effect; 3) cost is high, and drug loading is low: in coupling process, medicine feeding amount is far longer than HSA, and coupling drug amount is limited, causes preparation cost large (particularly antitumor drug expensive raw material price), the defect that system drug loading is low.
2. nanometer is passed medicine system: physical encapsulation medicine can significantly improve the load of carrier material to medicine.At present, the albumin nano granular of report preparation both at home and abroad or medicine carrying technique mainly contain: emulsifying coacervation, desolvation, pH coacervation and Nab technology.
Although first three methods research Applicative time is the longest, report is maximum, but still has a lot of problems:
1) particle diameter is large.Nanoparticle particle diameter 0.5-10 μ m, and be subject to operating condition impact, the albumin nano granular that is less than 200nm is several without report, and excessive particle diameter is unfavorable for that nano-carrier accumulates in tumor by the EPR effect of tumor;
2) need to solidify.Because HSA is highly water-soluble, prepared nanoparticle needs curing operation, adds chemical cross-linking agent to make albumin occur to be cross-linked or heat and makes albumen generation degeneration, and the former toxicity is larger, and easily make medicine occur crosslinked simultaneously and lose curative effect, latter is not suitable for the load of responsive to temperature medicine; In addition, somebody thinks that employing method crosslinked or that be heating and curing can reduce the hydrophilic on HSA nanoparticle surface, thereby reduces circulation time in blood, is unfavorable for cancer target;
3) aftertreatment technology complexity.Owing to having used the poisonous additives such as surfactant, oil, chemical cross-linking agent in technique, need clean purification with a large amount of organic solvents, but residually will bring hidden danger to drug safety on a small quantity; Adopt high speed centrifugation to separate (16000-20000g) and collect nanoparticle, not only high to instrument requirement, and in water, weigh bad dispersibility;
4) applicable medicine scope is little.Only be suitable for the load of water soluble drug, and quite a few antitumor drug is insoluble drug.
Nab technology is the medicine albumin-binding nanotechnology that America Biological Science Co., Ltd sets up in recent years.This technology is only suitable for the parcel of the fat-soluble medicine that plasma protein binding rate is higher.2005, the paclitaxel albumin-binding nanoparticle of preparing with this technology was (triumphant
) obtain FDA approval listing, after being mainly used in the failure of metastatic breast cancer combined chemotherapy or the breast carcinoma of recurrence in adjuvant chemotherapy 6 months.
Said preparation is with respect to traditional polyoxyethylene castor oil preparation (Thailand
) there is lower toxicity, better curative effect, but also there are many defects, comprising: the 1) use of toxic solvents.Employing chloroform is solvent, though there is vacuum evaporation operation, increased technology difficulty, and product may have dissolvent residual; 2) drug loading is low.Only can be controlled at 2-10wt%, need to consume a large amount of HSA; 3) inside and outside poor stability.Said preparation is under pH > 5.8 conditions, and medicine was very easily separated out in several hours, and therefore preparation pH value need be controlled within the scope of pH5.4-5.8 and (also only stablize 24h in this scope).And human internal environment's pH value is 7.4, after said preparation enters blood circulation, the specificity picked-up of tumor will be separated out from carrier and be unfavorable for to the expectation medicine short time, and dosage is safe clinically at present
1.5 times of preparation.
Because the preparation methoies such as ultrasonic technology all can not be used for the production of industrially scalable, and its diameter of particle obtaining is too large, and this makes it improper and can not be used for patient's administration and use.Therefore America Biology Science Co., Ltd has recorded and Docetaxel/paclitaxel of requiring protection high pressure homogenizing method respectively to prepare can to remake and human serum albumin's freeze-dried preparation in patent US2007082838 and CN98808225 and CN97199720, and after gained reconstruct, the stability of suspension exceedes 24 hours.
High shear technology has the functions such as superpower mixing, pulverizing, dispersion, emulsifying, has significant especially crushing effect for the macromolecular material such as SBS, SBR, can effectively solve pulverizing, an emulsifying difficult problem for all kinds of materials, has replaced traditional colloid mill equipment.Compared with traditional production technology, there is the advantages such as energy consumption is low, production cost is low, product quality is high, super-refinement.
In CN98808225 and CN97199720 patent, record also claimed delivery system that contains water-insoluble drug and protein-coated granule and preparation method thereof, wherein said average diameter of particles is 10-200nm.Described in it, the preparation method of drug regimen system is that the mixture of the organic facies containing described water-insoluble drug dispersion therein and proteinaceous aqueous medium composition is placed in the high pressure homogenizer of 3000-30000Psi, make it accept high shear treatment, produce above-mentioned granule, and said composition does not contain surfactant.
The inventor once repeatedly repeated the embodiment 1,5 and 6 of the embodiment, particularly CN97199720 of above-mentioned patent, illustrated result in the embodiment never obtaining in this patent and claim.The inventor has prepared disclosed mixture, in the pressure limit of then recommending at it, with Avestin high pressure homogenizer, mixture is processed, obtain the nano-emulsion of pH=6.8, and according to evaporating and removing desolventizing by rotary evaporator described in patent, can produce the nano-particle that mean diameter is about 220nm, after carrying out adding normal saline after lyophilization, be easy to recasting and become suspension, but its nano-particle size compared with lyophilization before obviously increase, mean diameter is increased to 390nm by the 220nm before lyophilization, and in 4h, there is the precipitation of nano-particle.In addition, filter with the microporous filter membrane of being recorded in patent CN97199720, be easy to occur stopping up, and medicine productive rate is lower than 30% but result is filter, these are different from the yield results of the 70-100% stating in patent.
In US2007082838 patent, record and the claimed albumin nano granular that comprises Docetaxel medicine that adds stabilizing agent sodium citrate and/or sodium chloride; its mean diameter < 200nm; and described in patent; these use the nano-emulsion obtaining higher than homogenizing method to it is said very high stability; the meaning of term " stability " had both represented that mean diameter was not in time or freezing dry process and changing herein; also represent not occur the drug precipitation (US200708283, embodiment 12) of nano-particle.
The inventor once repeatedly repeated the embodiment 11,16 of the embodiment, particularly US200708283 of above-mentioned patent, and 18, never obtain disclosed result in this patent working example and claims.The inventor has prepared disclosed mixture, then in the pressure limit of its recommendation, with Avestin high pressure homogenizer, it is processed, obtain the nano-emulsion of pH=7.2, utilize rotary evaporator evaporation to remove after organic solvent, produce the nano-particle of the about 280nm of mean diameter.But there is very soon the precipitation of nano-particle, carrying out described filtering with microporous membrane (1.2um, 0.8um, 0.45um and 0.22um) time more difficult, easily there is situation about stopping up in filter membrane, and the nanosuspension that its lyophilized products forms after remaking in physiological solution is unstable, occurs macroscopic precipitation in approximately 8 hours, it is completely different that the stability of claiming in these and patent is greater than the result of 24 hours.
Summary of the invention
The object of the invention is the problems referred to above and shortcoming for prior art, the invention provides the protein nano granule of the clinical practice character that a kind of preparation technology is simpler, character is more stable and better.
Another object of the present invention is to provide the preparation method of above-mentioned protein nano granule.
The inventor stumbles in the process of preparing protein nano granule, when by water-solubility carrier material (as, Polyethylene Glycol, mannitol, PVP, etc.) add after protein system, the protein nano granule of bag loaded taxane class medicine more easily forms, particle diameter is even simultaneously, and stability improves.In order to investigate this effect of water-solubility carrier material in system, the inventor studied water-solubility carrier material and protein-based between relation, surprisingly, the result of transmission electron microscope and means of differential scanning calorimetry all reflects, this the two be not simple mixed system, but formed a kind of new compound system by interaction.We infer the formation due to this new compound system, taxone can better be carried by bag, thereby preparation technology's operability is significantly promoted, and make nano-particle more stable and more even simultaneously.
Due to the significant advantage of this new compound system, the inventor attempts this water-solubility carrier first to mix with taxone then, taxone is present in water-solubility carrier with the form of molecular dispersion, the two adds in protein-based solution with the form of solid dispersion, mixes and pass through the protein nano granule of the effect formation taxone of high shear force.Found that protein nano granule more easily forms, stability is better; Meanwhile, this nano-particle has the long circulation of obvious blood and tissue, organ targeting, has better pharmacodynamic properties.
The invention provides a kind of preparation method that taxone (as paclitaxel, Docetaxel, etc.) is joined to a Nano grade carrier with the form of molecular dispersion state.The method more easily obtains taxone nano-particle (average diameter is less than 200 nanometers) than nab technology, and do not need to add any poisonous organic solvent (as, dichloromethane, chloroform, etc.), avoid residual in preparation of organic solvent, greatly improved the safety of clinical application.
Meanwhile, the invention provides a kind of protein nano granule, this protein nano granule is high to taxone drug loading, can significantly reduce the consumption of protein substance; This protein nano granule also possesses good inside and outside stability, and liquid preparation can be stablized preservation at ambient temperature for a long time, improves medication convenience and safety.The nano-particle of the taxone that the method obtains has the long circulation of obvious blood and tissue, organ targeting, therefore possesses better pharmacodynamic properties.In sum, the invention provides the protein nano granule of the clinical practice character that a kind of preparation technology is simpler, character is more stable and better.This protein nano granule have particle diameter evenly, good stability, the good high feature of safety.
The object of the invention is to realize by following technical proposal:
Wrap up a protein nano granule for taxone, the formula of this protein nano granule contains the material of following percentage by weight:
0.1～10% taxone, 0.1～40% water-solubility carrier material, 50～90% protein substances.
Described protein nano granule, wherein taxone is selected from one or more in following material: paclitaxel, Docetaxel, or their derivant.
Described protein nano granule, wherein said water-solubility carrier material is selected from one or more in following material: Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, polyethylene oxide, mixed aliphatic ester, mannitol, carbamide, sodium alginate, HPMC, polyacrylic resin, gelatin, sodium carboxymethyl cellulose.
The alleged protein substance of the present invention refers to can be by the following material of sulfydryl and/or disulfide bond crosslinking: natural existence or synthetic protein and derivant thereof, synthetic protein polymer and derivant thereof, natural or synthetic albuminoid and derivant thereof, or their mixture.
Described naturally occurring protein comprises that albumin, immunoglobulin, casein, lipoprotein, hemoglobin, lysozyme, α-2-macroglobulin, fibronectin, glass connect element, Fibrinogen, lipase; Described synthetic protein polymer is selected from one or more in the following material that contains free sulfhydryl groups and/or disulfide group modification: PVOH, poly-ethyl oxazoline, polyacrylamide, polyvinylpyrrolidone, polyglycols, PGA, polycaprolactone or its copolymer, synthetic polyamino acid.
The preparation method of described protein nano granule, the method comprises the following steps:
A. taxone and water-solubility carrier material are made to the water-solubility carrier solid dispersion that contains taxone;
B. the solid dispersion of gained is added in the aqueous medium containing protein substance, mix homogeneously, mixture has obtained wrapping up the suspension of the protein nano granule of taxone through shear conditions processing;
C. suspension is dried or is first dried again through aseptic filtration, make solid preparation, semi-solid preparation or the gas preparation of the protein nano granule that has wrapped up taxone by required dosage form;
Or
Step b is obtained to suspension directly as liquid preparation or be further prepared into the liquid preparation of other types or by dry suspension or first redissolve and make liquid preparation again after aseptic filtration is dry again.
Described preparation method, wherein aqueous medium is selected from water for injection, pure water, mannitol solution, aqueous phosphatic, dextran solution, D/W, sodium-chloride water solution, Freamine Ⅲ, vitamin solution, carbohydrate solutions, or their any two or more mixture.
Described preparation method, the method for the water-solubility carrier solid dispersion that wherein preparation contains taxone is fusion method, solvent method, solvent-fusion method, solvent-spraying (freezing) seasoning, polishing or Double helix squeezing and pressing method; And these methods are not introduced any organic solvent or any other organic solvents except ethanol; Preferably adopt solvent-fusion method; (method such as fusion method, solvent method, solvent-fusion method is to prepare the conventional method of solid dispersion.For example, by dissolve with ethanol for medicine (solvent), water-solubility carrier heating and melting (melting), both mix, and this is solvent-fusion method.Again for example, by medicine heating and melting, water-solubility carrier heating and melting, both mix, and this is fusion method.If solvent-fusion method, for " not needing to introduce any other organic solvents except ethanol ", only use ethanol.If fusion method is " not needing to introduce any organic solvent ".What the present invention preferably adopted is solvent-fusion method, the advantage that solvent-fusion method is compared fusion method is: the direct melting of some medicine, can cause excess Temperature, degrade, stability can not guarantee, therefore this patent mainly adopts solvent-fusion method, specifically adopts which kind of method to determine according to the character of the medicine of selecting and carrier.)
Described shear conditions refers to that application possesses the equipment of high pressure and high shearforce simultaneously, makes mixture reach efficient mixing, pulverizing, dispersion and emulsifying object; Wherein, high pressure refers to that pressure limit is at 5000 to 30000 pounds/inch
2, preferably 6000～25000 pounds/inch
2.
Described preparation method, wherein the mean diameter of this protein nano granule is 20～1000nm, is preferably 20～200nm.
Described preparation method, wherein drying means adopts lyophilization or spraying to be dried; Aseptic filtration adopts 0.22 μ m filter to filter.
In detail, the present invention is to provide a kind of preparation method that taxone (as paclitaxel, Docetaxel, etc.) is joined to a Nano grade carrier with the form of molecular dispersion state.The method more easily obtains the little nano-particle of taxone (average diameter is less than 200 nanometers) than nab technology, and does not need to add any poisonous organic solvent (as, dichloromethane, chloroform, etc.).The nano-particle of the taxone that the method obtains is more stable, and drug loading is high, has the long circulation of obvious blood and tissue, organ targeting, therefore possesses better pharmacodynamic properties.
The method provides a kind of method that forms the nano-particle of taxone by desolventizing technology, such as, high shear force (as ultrasonic, high-pressure homogenization effect or conditions of similarity) can be used to form the substrate of nano-particle under the condition that lacks any conventional surfactants and any polymerization core substance.
The method provides the preparation method of a kind of reusable little nano-particle (diameter is less than 200 nanometers), and this granule can pass through 0.22 micron of filter aseptic filtration.This certain size the preparation of nano-particle of filtering by 0.22 micron of filter is significant, because the preparation that contains a large amount of any protein (as albumin) all can not carry out disinfection as autoclaving by conventional method, because heat can make albuminous degeneration.Certainly, if adopt the larger filter in aperture also the mean diameter of granule can be controlled to 1000nm left and right, but the present invention is preferably controlled at 20～200nm by the mean diameter of granule.
In aqueous medium, add the concentration range of protein substance (for example, human serum albumin) be about 0.05-25% (w/v, g/ml, lower with), scope among 0.5%-10% (w/v) better.These aqueous mediums have aqueous medium, Freamine Ⅲ, vitamin solution, carbohydrate solutions or the similar medium of normal saline, buffer saline, water, buffering, and the mixture of any two or more these medium.Different from conventional nano-particle formation method, in mixture, do not need to add surfactant (for example, sodium lauryl sulphate, lecithin, Tween 80, poly alcohol F68 and similar compound etc.) or poisonous organic solvent (for example, dichloromethane, chloroform etc.).
By taxone (paclitaxel, Docetaxel etc.) and water-solubility carrier (as, Polyethylene Glycol, polyvinylpyrrolidone, poloxamer etc.) be prepared into the solid dispersion (powder) of a kind of taxone and water-solubility carrier by methods such as fusion method, solvent method or melting solvent methods.The formation of this solid dispersion does not need to introduce any other organic solvents except ethanol, even do not need to introduce organic solvent, avoid residual in preparation of organic solvent (as chloroform, dichloromethane etc.), greatly improved the safety of clinical application.
Under low-shearing force, form a kind of mixture being formed by micron and nanometer droplet through homogenization.This can be by well known to a person skilled in the art that mode completes, and for example, adopts a kind of opereating specification at the Routine Test Lab pressure-even pulp crusher of about 2,000 to about 15,000 revs/min.
Medicament-carried nano granule is under high shear condition to form through homogenization.This homogenization is carried out conventionally in high-pressure homogenate device, and typical operating pressure is at 5,000 to 30,000 pounds/inch
2scope in, this process is at 6,000 to 25,000 pounds/inch
2in scope, carry out better.The Emulsion generating is containing imperceptible aqueous carrier nanometer droplet (containing the pharmacological active substance of dissolving etc.) and imperceptible protein nano droplet.Acceptable homogenization process comprises can give high shear and cavitation, as high-pressure homogenate device, ultrasonic processor, high-shear mixer, and similar devices.
Liquid suspended matter can drying obtains the powder of the protein nano granule that wraps up taxone.The powder generating can in any suitable time and in suitable aqueous medium redispersion obtain can be to the suspension of mammal administration.These aqueous mediums have aqueous medium, Freamine Ⅲ, vitamin solution, carbohydrate solutions or the similar medium of normal saline, buffer saline, water, buffering, and the mixture of any two or more these medium.Comprise that for obtaining method that this powder adopts lyophilization, spraying are dry, and similar technology.
The moisture including by removing it for example, can further convert powder type to vacuum freeze-drying method in suitable temperature-time range.Protein (for example; human serum albumin) itself play cryoprotective agent effect; do not need to use conventional freezing protective agent as mannitol, sucrose, glycerol, and similar compound, and this powder is by adding water, normal saline or buffer easily to recombinate.Although do not need, certainly can understand into as very necessary, these conventional cryoprotective agents can join in formula of the present invention.
According to an embodiment of the invention, provide a submicron particles (nano-particle) that formation is very tiny, diameter is less than the method for the granule of 200 nanometers.This granule can carry out aseptic filtration before using in liquid suspension mode.Process for preparation gained final products of the present invention (being drug particles) can aseptic filtration be significant, because can not be by conventional method if autoclave be to for example, carrying out sterilizing containing the suspension of high concentration protein (, human serum albumin).
The application of the protein nano granule of described parcel taxone in pharmacy, this protein nano granule can be used for gastrointestinal administration and parenteral administration.The dosage form of this protein nano granule can be solid dosage forms, semisolid dosage form, liquid dosage form and gas dosage form, comprises lyophilized powder, capsule, granule, ointment, paste, suspensoid, injection, spray, inhalant etc.
In the enforcement of this invention, the protein substance of many biocompatibility can be used for preparing the carrier shell of protein nano granule, is wrapped in the outside of taxone.In fact any protein substance, natural or synthetic, as long as can contain sulfydryl or disulfide bond in its structure as required, just can be for formation one deck disulfide bond crosslinking shell around taxone.Sulfydryl or disulfide bond can preexist in polymer architecture maybe and can import by suitable chemical modification, such as naturally occurring polymer as protein, peptide, polynucleotide, polysaccharide (as starch, cellulose, glucosan, Algin, chitosan, pectin, hyaluronic acid etc.), proteoglycan, lipoprotein etc. are all the candidates with this modification.
Protein-based albumin (containing 35 cysteine), immunoglobulin, casein, lipoprotein, hemoglobin (each α of comprising in the present invention
2β
2unit contains 6 cysteine residues), lysozyme (containing 8 cysteine residues), immunoglobulin, α-2-macroglobulin, fibronectin, glass connect element, Fibrinogen, lipase etc.Wherein protein, peptide, enzyme, antibody and their mixture thereof are the protein substances of the conventional application of the present invention.
Albumin for preferred protein substance of the present invention at present.For example α-2-macroglobulin (a kind of known opsonin), can, for strengthening huge picked-up of biting the taxone of like cell to carrier parcel, maybe can promote the taxone of this carrier parcel to enter into liver and spleen.
Equally, the synthetic polypeptide that contains cysteine residues is also the good candidate that forms the protein substance of shell in the periphery of taxone.In addition, polyvinyl alcohol, poly hydroxyethyl methylacrylate, polyacrylic acid, PEOz, polyacrylamide and polyvinylpyrrolidone etc. are all chemical modification (as introduced sulfydryl and/or disulfide bond), and form the good candidate of shell (as causing crosslinked).So the example that is designed for these materials of the invention process is, the synthetic amino acids that contains cysteine residues and/or disulfide bond; Polyvinyl alcohol, contains free sulfhydryl group and/or disulfide bond after modified; Poly hydroxyethyl methylacrylate, contains free sulfhydryl group and/or disulfide bond after modified; Polyacrylic acid, contains free sulfhydryl group and/or disulfide bond after modified; Ju ethoxazole quinoline, contains free sulfhydryl group and/or disulfide bond after modified; Polyacrylamide, contains free sulfhydryl group and/or disulfide bond after modified; Polyvinylpyrrolidone, contains free sulfhydryl group and/or disulfide bond after modified; Polyglycols, contains free sulfhydryl group and/or disulfide bond after modified; Polyactide, PGA, polycaprolactone, or their copolymers, contain free sulfhydryl group and/or disulfide bond after modified; And any two or more mixture of above-mentioned material.
Beneficial effect of the present invention
The invention provides a kind of preparation method of the protein nano granule that wraps up taxone, the method is encapsulated in the taxone granule of suspendible a kind of by can biocompatible composition polymer housing, and its diameter is nanoscale.The method does not need to introduce any other organic solvents except ethanol, even do not need to introduce organic solvent, avoid organic solvent (as chloroform, dichloromethane etc.) residual in preparation, and can not produce the anaphylaxis causing because adding cosolvent or emulsifying agent, greatly improve the safety of clinical application; The method does not need to use conventional surfactant yet.The method provides a kind of and more easily forms and more stable taxone nano-particle, and the method technique is simple, cost is low, strong operability.The method the present invention provides the preparation method of the nano-particle of a kind of energy aseptic filtration simultaneously.
Meanwhile, the invention provides a kind of protein nano granule, this protein nano granule is high for the drug loading of taxone, can significantly reduce the consumption of protein substance; This protein nano granule also possesses good inside and outside stability, and liquid preparation can be stablized preservation at ambient temperature for a long time, improves medication convenience and safety.The nano-particle of the taxone that the method obtains has the long circulation of obvious blood and tissue, organ targeting, therefore possesses better pharmacodynamic properties.In sum, the invention provides the protein nano granule of the clinical practice character that a kind of preparation technology is simpler, character is more stable and better.This protein nano granule has the features such as drug loading is high, particle diameter even, good stability, safety height.
Accompanying drawing explanation
Fig. 1 is that fusion method is prepared paclitaxel albumin nanometer formulation intensity particle size distribution figure.(vertical coordinate is intensity percent (%), and abscissa is particle diameter (nm), and Fig. 2, Fig. 7-Figure 11 are all roughly the same.)
Fig. 2 is that melting-solvent evaporation method is prepared paclitaxel albumin nanometer formulation intensity particle size distribution figure.
Fig. 3 is WAXD figure.Wherein: sample a: paclitaxel powder, sample b: Lyophilized Human serum albumin powder, sample c: paclitaxel and albuminous physical mixture, sample d: formulation for paclitaxel sample.
Fig. 4 is DSC figure.Wherein: sample a: Lyophilized Human serum albumin powder, sample b: paclitaxel powder; Sample c: paclitaxel and albuminous physical mixture; Sample d: formulation for paclitaxel sample.
Fig. 5 is transmission electron microscope picture.Wherein: sample a: human serum albumin's freeze-dried powder, sample b: Polyethylene Glycol albumin powder, sample c: paclitaxel albumin nanometer formulation freeze-dried powder.
Fig. 6 is fluorescent scanning figure.In figure, along with curve a → h direction, Polyethylene glycol increases.
Fig. 7 is Docetaxel albumin nanometer formulation intensity particle size distribution figure.
The specific embodiment
The invention will be further elaborated by the following examples.
500 milligrams of paclitaxels are dissolved in to 9.0 milliliters of ethanol.1200 milligrams of Polyethylene Glycol heat after complete melting in 60 ℃ of oil baths, and paclitaxel solution is added wherein, and magnetic agitation is until its complete mix homogeneously, and rotary evaporation is removed after ethanol, cooling rapidly under intense agitation.After vacuum drying spends the night, solid dispersion is added in 85 milliliters of human serum albumin's aqueous solutions (4.5%w/v, g/ml, lower with).Mixture, is then transferred in high pressure homogenizer (EmulsiFlex-05, Canadian Avestin company) to form thick breast through high speed disperser (XHF-1, Shanghai Jin Da biochemical instrument factory) premix 1 minute.High pressure homogenize is at 5000-30,000 pound/inch
2condition under carry out, by Emulsion repetitive cycling at least 5 times, obtain protein nano granule suspension, the product of acquisition has denseer opalescence.Measure through laser particle instrument (Nano-ZS90, Malvern company of Britain), the general diameter of paclitaxel albumin nanometer rice grain that result obtains is in 130-220 nanometer, and result as shown in Figure 1.
Protein nano granule suspension is further lyophilizing 48 hours in the situation that not adding any cryoprotective agent, and the powder obtaining can be easy to reconstitute protein nano granule suspension by adding sterilized water or normal saline.Roughly the same before the size of granule and lyophilizing after reconstruct.
300 milligrams of paclitaxels are dissolved in to 6.0 milliliters of ethanol.900 milligrams of Polyethylene Glycol are dissolved in 1.5 milliliters of dehydrated alcohol, heat after complete melting 45 ℃ of oil baths, and paclitaxel solution is added wherein, and magnetic agitation is until its complete mix homogeneously, and rotary evaporation is removed after ethanol, cooling rapidly under intense agitation.After vacuum drying spends the night, solid dispersion is added in 65 milliliters of human serum albumin's aqueous solutions (4.5%w/v).Mixture, is then transferred in high pressure homogenizer (EmulsiFlex-05, Canadian Avestin company) to form thick breast through high speed disperser (XHF-1, Shanghai Jin Da biochemical instrument factory) premix 1 minute.Be emulsified in 5000-30,000 pound/inch
2condition under carry out; by Emulsion repetitive cycling at least 6 times; obtain protein nano granule suspension; the product obtaining has denseer opalescence; through laser particle instrument (Nano-ZS90; Malvern company of Britain) to measure, the general diameter of paclitaxel albumin nanometer rice grain that result obtains is in 120-200 nanometer, and result is as shown in Figure 2.
Protein nano granule suspension is further lyophilizing 48 hours in the situation that not adding any cryoprotective agent, and the powder obtaining can be easy to reconstitute protein nano granule suspension by adding sterilized water or normal saline.Roughly the same before the size of granule and lyophilizing after reconstruct.
Embodiment 3 be less than 200 nanometers can aseptic filtration the preparation of paclitaxel albumin nanometer rice grain
500 milligrams of paclitaxels are dissolved in to 9.0 milliliters of ethanol.800 milligrams of Polyethylene Glycol are dissolved in 1.5 milliliters of dehydrated alcohol, heat after complete melting 45 ℃ of oil baths, and paclitaxel solution is added wherein, and magnetic agitation is until its complete mix homogeneously, and rotary evaporation is removed after ethanol, cooling rapidly under intense agitation.After vacuum drying spends the night, solid dispersion is added in 97 milliliters of human serum albumin's aqueous solutions (4.5%w/v).Mixture, is then transferred in high pressure homogenizer (EmulsiFlex-05, Canadian Avestin company) to form thick breast through high speed disperser (XHF-1, Shanghai Jin Da biochemical instrument factory) premix 1 minute.Be emulsified in 10000-40,000 pound/inch
2condition under carry out; by Emulsion repetitive cycling at least 6 times; obtain protein nano granule suspension; the product obtaining has denseer opalescence; through laser particle instrument (Nano-ZS90; Malvern company of Britain) to measure, the general diameter of paclitaxel albumin nanometer rice grain that result obtains is in 120-170 nanometer.
Protein nano granule suspension filters by the micropore filter of 0.22 micron, and turbidness or granular size are without any change.The HPLC of content of taxol analyzes and shows after exceeding 95% paclitaxel filters recyclablely, and result is as shown in table 1.The method can provide a kind of aseptic paclitaxel albumin nanometer suspension.
Sterile suspension is further lyophilizing 48 hours in the situation that not adding any cryoprotective agent, and the powder obtaining can be easy to reconstitute protein nano granule suspension by adding sterilized water or normal saline.Roughly the same before the size of granule and lyophilizing after reconstruct.
Table 1
Embodiment 4 judges the physical state of paclitaxel in form of nanoparticles by X-ray powder diffraction
X-ray powder diffraction can be used for judging crystallization or the noncrystalline characteristic of paclitaxel in freeze drying powder preparations.According to X-ray diffraction (X-ray diffraction) principle, the peak shape of diffraction maximum is main relevant with imperfection and the crystal structure of crystal, i.e. defect and distortion etc. in size, the crystal of crystallite dimension.According to Scherrer formula (Scherrer Equation), the square root of crystallite dimension and diffraction maximum is inversely proportional to, and the size of crystallite dimension reflects its degree of crystallinity height, the i.e. wider lower degree of crystallinity of diffraction maximum correspondence.
Take a small amount of sample a-paclitaxel powder; Sample b-Lyophilized Human serum albumin powder; Sample c-paclitaxel and albuminous physical mixture; With sample d-paclitaxel albumin nanometer rice grain freeze-dried powder (by embodiment of the present invention preparation), XD-3A powder diffractometer carries out powder X-ray diffraction test.5～40 ° of the angles of diffraction, 1 °/min of scanning speed, running voltage 40kV, carries out powder X-ray diffraction test under operating current 50mA condition, and result is as shown in Figure 3.
Sample a show sample has been located three strong diffraction maximums at 5.28 °, 8.84 ° and 12.36 °, has some little diffraction maximums between 15～25 °.Sample b has shown the typical broadband of amorphous substance protuberance.Sample c has shown the typical broadband of amorphous substance protuberance, but can see in addition 5.28 °, 8.84 ° and 12.36 ° of characteristic peaks of locating.Sample d formulation for paclitaxel does not demonstrate paclitaxel and has the evidence of crystallization characteristic, but very similar to the amorphous substance broadband protuberance of sample b, prompting paclitaxel is actually and exists with molecularity or unformed state in nanometer formulation, thereby shows that drug taxol is really present in albumin nanometer carrier after high pressure homogenize.
The DSC collection of illustrative plates of embodiment 5 paclitaxel albumin nanometer rice grains
Differential scanning calorimetry (Differential Scanning Calorimetry, DSC) is under temperature programmed control, to measure a kind of technology of the difference power and the temperature relation that are input to sample and reference sample.When crystal melting, to absorb energy (J) to destroy lattice, endergonic how many relevant with crystal structure, characteristic constant heat content (Δ H, the Jg of unit of molecule specific crystal formation
-1) can characterize its crystal formation feature.
Take sample a-Lyophilized Human serum albumin powder; Sample b-paclitaxel powder; Sample c-paclitaxel and albuminous physical mixture; With the each 2～3mg of sample d-paclitaxel albumin nanometer rice grain freeze-dried powder (by embodiment of the present invention preparation), the heating rate heating through NETZSCH-DSC 204 analysers with 10 ℃/min, 50～300 ℃ of temperature ranges, blanket of nitrogen is carried out dsc analysis.Result as shown in Figure 4.
As seen from the figure, curve a shows that albumin has little dehydration exothermic peak at 67.4 ℃, and there is melting peak slowly 222.3 ℃ of left and right; In curve b, 224.2 ℃ of endothermic peaks and 244.5 ℃ of exothermic peaks are respectively melting peak and the degradation peak of paclitaxel, these two characteristic peaks be present in simultaneously paclitaxel and albuminous physical mixture (curve c) in, and be not present in paclitaxel albumin nanometer formulation (curve d) in.Above spectrum data shows that medicine is present in micelle skeleton with the form of unformed or solid solution.
The morphology research of embodiment 6 paclitaxel albumin nanometer rice grains
Take sample a-human serum albumin freeze-dried powder, sample b-Polyethylene Glycol albumin powder and sample c-paclitaxel albumin nanometer rice grain freeze-dried powder (by embodiment of the present invention preparation) appropriate, with the abundant hydration of 5% glucose solution, obtain light blue opalescence micellar solution, the dyeing of phosphotungstic acid negative staining, getting 1 micellar solution to be measured drips in the groove of drop reaction porcelain plate, and carbon-sprayed copper net is put on test solution, after 1～2min, take out copper mesh, suck residual liquid from copper mesh edge with filter paper small pieces; This copper mesh is placed on to dye liquor and drips (4% Salkowski's solution, pH 7.0) upper about 30s, blot unnecessary dye liquor, dry, through the H-7000 of Hitachi transmission electron microscope observing form, result as shown in Figure 5.
As shown in the figure, human serum albumin can not form spherical structure, but is dispersed into homogeneous solution state; Add the human serum albumin after Polyethylene Glycol to demonstrate more regular spherical structure, particle diameter is 100nm left and right; And medicine carrying albumin preparation forms more regular and intensive spherical structure, particle diameter is 120nm left and right, and particle size distribution is even.Simultaneously known, the transmission electron microscope particle diameter result of sample b, sample c is less than respectively the particle diameter (being respectively 122nm and 138nm) of dynamic light scattering experiment gained, and this may be because the dry run in TEM sample preparation process causes due to subsiding of micellar surface.
The interactional fluorescent spectrometry research of embodiment 7 Polyethylene Glycol and human serum albumin
In human serum albumin, contain trp residue, tryptophan can produce stronger fluorescence under ultraviolet excitation.It is known that fluorescence is swept spectrum result, and human serum albumin's fluorescence maximum excitation wavelength is at 285nm, and maximum emission wavelength is in 350nm left and right.
Many small-molecule drugs or water-solubility carrier can influence each other with albumin, thereby cause fluorescent quenching.According to this principle, we can do series of experiments and prove the interaction between other materials and albumin.
In 10ml color comparison tube, add successively 1.0 × 10 of 1.0mL
-5mo lL
-1human serum albumin solution and different volumes 1.0 × 10
-4molL
-1polyglycol solution, is diluted with water to scale, shakes up, and constant temperature 10min hatching in water bath with thermostatic control, fixing Kex=285nm, Kem=350nm, measure relative intensity of fluorescence ^F=F
0-F (F, F
0system solution fluorescence intensity when being illustrated respectively in Polyethylene Glycol existence and existing without Polyethylene Glycol), result is (IF is the unit of fluorescence intensity, and subscript F is the meaning of fluorescence fluorescent) as shown in Figure 6.
Known according to fluorescence result, under the condition of 25 ℃, Polyethylene Glycol produces quenching effect to the endogenous fluorescence of human serum albumin.Along with the rising of Polyethylene glycol, (fluorescence intensity weakens simultaneously for curve a → h), albuminous fluorescent emission wavelength generation blue shift.Result shows to have produced take Van der Waals force as main interaction between Polyethylene Glycol and albumin, thereby makes albumin that regular fluorescent quenching occur, and its quenching mechanism meets dynamic quenching.
The impact of embodiment 8 drug level on paclitaxel albumin nanometer rice grain size
Change the concentration of paclitaxel, keep other parameters and in embodiment 2, describe identically, prepared a series of paclitaxel albumin nanometer formulations.Measure and find that lower drug level can generate diameter and be approximately the granule of 160 nanometers through laser particle instrument, higher concentration generates less granule, and diameter is approximately 120 nanometers.In the time that the concentration of paclitaxel in human serum albumin solution is 1 mg/ml, particle diameter is 250 nanometer left and right; In the time that the concentration of paclitaxel in human serum albumin solution is 2 mg/ml, particle diameter is 180 nanometer left and right; In the time that the concentration of paclitaxel in human serum albumin solution is 5 mg/ml, particle diameter is 130 nanometer left and right.
The compatibility stability of embodiment 9 common infusion fluid agent
Investigated paclitaxel albumin nanometer lyophilized formulations (by embodiment of the present invention preparation) and common infusion fluid agent (as, 5% glucose solution, 0.9% normal saline) compatibility stability, for clinical use provides reference.Generally speaking, dilution stability only need reach 8h can meet clinical practice, and therefore the present embodiment is take particle diameter, content of taxol compatibility stability in index is evaluated its 8h.
Experimental result shows, paclitaxel albumin nanometer lyophilized formulations all can obtain the solution of opalescence homogeneous after redissolving with 5% glucose or 0.9% normal saline, and as shown in Table 2, in 8h, each index is all without significant change.Therefore, 5% glucose and 0.9% normal saline all can be used as the redissolution medium of paclitaxel albumin nanometer rice grain lyophilized formulations when clinical use.
Table 2
Particle diameter and the potential change of paclitaxel albumin nanometer rice grain before and after embodiment 10 lyophilizing
Zetasizer 3000HS laser particle size analyzer is by measuring after paclitaxel albumin nanometer freeze-dried powder (by embodiment of the present invention preparation) redissolution, mean diameter increases slightly compared with before lyophilizing, polydispersity index does not change, the basic character that paclitaxel albumin nano granular is described does not change before and after lyophilizing, has guaranteed the stable of paclitaxel albumin nanometer formulation by cryodesiccated solid state process.
In addition, Zeta potential substantially remains unchanged before and after lyophilization, all between-32～-36mV.Generally speaking, in the time of the absolute value > of Zeta potential 30mV, because nanoparticle surface exists a large amount of electric charges, between nanoparticle, there is larger repulsive force, and be conducive to nanometer solution stablize and impel nanoparticle size homogeneous.The equal > 30mV of paclitaxel albumin nanometer rice grain Zeta electric potential absolute value, indicates that both all have good physical stability, and concrete outcome is as shown in table 3.
Table 3
The stability of paclitaxel albumin nanometer formulation after embodiment 11 reconstruct
Investigated paclitaxel albumin nanometer lyophilized formulations after 0.9% normal saline redissolves stability, for clinical use provides reference, take particle diameter, drug level compatibility stability in index is evaluated its 8h.
Lyophilizing paclitaxel albumin nanometer formulation in cillin bottle (by embodiment of the present invention preparation) is redissolved to concentration and is respectively 1,2,5 mg/ml with normal saline, and be stored in room temperature state.Measure respectively its particle diameter and medicament contg in different time points, suspension was at least stable in 7 days.Wherein as shown in table 4 for 5 mg/ml preparations concrete particle diameter and content of dispersion.
Table 4
The mouse tissue of embodiment 12 paclitaxel albumin nanometer formulations distributes and tests
450 of female white mice of healthy Kunming kind choosing body weight 20 ± 2g, fasting 12h, is divided into 75 groups at random, by 15mg/kg dosage tail vein injection Thailand respectively
(Bristol-Myers Squibb Co. of the U.S.), triumphant
(America Biological Science Co., Ltd) and paclitaxel albumin nanometer formulation (by embodiment of the present invention preparation), after administration respectively at 5,15min and 0.5,1,3,8,12,24h time point get one group (n=6), eyeball is got after blood respectively, cervical vertebra dislocation is put to death, and cores, the internal organs such as liver, spleen, lung, kidney, brain, tumor.Whole blood is placed in heparin sodium test tube, centrifugal, separated plasma; Internal organs normal saline flushing, filter paper blots its moisture, weighed total amount (blood is by 8% of Mouse Weight).Extract sample introduction after the medicine in biological sample, record medicine peak area, calculate blood plasma and respectively organize the drug level of different time.According to drug level temporal evolution curve calculation AUC, MRT and targeting efficiency.Different time drug level is as shown in the table, and wherein table 5 is safe
respectively organize Chinese medicine through time concentration, table 6 is triumphant
respectively organize Chinese medicine through time concentration, table 7 for paclitaxel albumin nanometer formulation respectively organize Chinese medicine through time concentration.
Table 5 Thailand
respectively organize Chinese medicine through time concentration (ng/ml)
Table 6 is triumphant
respectively organize Chinese medicine through time concentration (ng/ml)
Table 7 paclitaxel albumin nanometer formulation respectively organize Chinese medicine through time concentration (ng/ml)
From result: respectively organize Chinese medicine through time concentration
1) Thailand
triumphant
be respectively 38.45,75.72,236.52 with the AUC value of paclitaxel albumin nanometer formulation; MRT is respectively 11.75,17.42,26.41;
2) Thailand
triumphant
be respectively 1,1.969,6.151 with the relative uptake ratio Re of tumor of paclitaxel albumin nanometer formulation; Demonstrate this preparation tumor-targeting stronger with respect to triumphant element.
3) Thailand
triumphant
be respectively 0.88,5.97,10.76 with the cancer target efficiency Te of paclitaxel albumin nanometer formulation; Demonstrate the better tumor-targeting of this preparation.
The rat pharmacokinetics experiment of embodiment 13 paclitaxel albumin nanometer rice grains
Get 12 of SD rats (favorable to the people scientific and technological animal cultivation field, Prevalence In Qixia District, Nanjing City provides), be divided at random 4 groups, 3 every group, give respectively Thailand
triumphant
with paclitaxel albumin nanometer formulation (by embodiment of the present invention preparation).With the dosage of 7mg/kg by tail vein injection administration, respectively at after administration 5,15,30min, 1,2,4,6,8,12,24,36h eye socket is got the about 0.5mL of blood, is placed in the centrifuge tube that is added with heparin sodium centrifugal 10min (6000r/min) separated plasma.Add 4mL t-butyl methyl ether after vortex centrifugal, extract paclitaxel and internal standard substance diazepam in blood plasma, measure the content of taxol in each time point blood plasma with high performance liquid chromatograph (LC-2010C, Japanese Shimadzu), determination data is as shown in table 8.
Table 8
Result shows, the blood circulation time that this preparation group can significant prolongation paclitaxel, and this may be because the backbone of Polyethylene Glycol softness can significantly reduce the probability that carrier is engulfed by endothelium reticular system.In addition, the mean residence time of this preparation (MRT) and blood medicine through time concentration curve under area (AUC) be significantly higher than triumphant
injection (P < 0.01), is respectively triumphant
1.90 and 1.79 times.
The pharmacodynamic experiment of embodiment 14 paclitaxel albumin nanometer rice grains
Get 40 of BALB/c tumor-bearing mices, be divided at random 4 groups, 10 every group, gave respectively sample 1-Thailand in 3,5,7,9 days
sample 2-is triumphant
sample-3 paclitaxel albumin nanometer formulation (by embodiment of the present invention preparation) and sample 4-normal saline, with the dosage of 10mg/kg, by tail vein injection administration, investigation index is as follows:
1. tumor growth curve: survey major diameter a and the minor axis b of a tumor with slide gauge in every two days, according to formula V=0.5 × a × b
2calculate the volume of tumor, draw tumor growth curve;
2. inhibition rate of tumor growth: when experiment finishes, put to death mice, peel off tumor, take tumor weight, calculate tumor growth inhibition percentage: inhibition percentage TI (%)=(1-WT/WC) × 100% according to following formula, the average tumor weight that wherein WT is treatment group, the average tumor weight that WC is matched group;
3. body weight change curve: measure the body weight of mice every day, draw the body weight change curve of mice.Exceed 20% if Mouse Weight reduces, can think that medicine has produced toxicity.
Result is as shown in table 9 below, calculates relative tumor rate of growth by the gross tumor volume of each time point, and result shows, paclitaxel albumin nanometer formulation is with respect to Thailand
with triumphant
more effectively suppress the growth of MDR tumor.
Table 9
As shown in table 10, the heavy result of tumor after dissection shows, with respect to the average tumor weight of normal saline group, Thailand
the inhibition rate of tumor growth of group is 60%, triumphant
group is 53%, and preparation group is 66%.
Table 10
As shown in table 11, change known triumphant by tumor heavy (g)
group and this preparation group are showed no overt toxicity, but in intravenous injection Thailand
after, the mice phenomenon such as occur being slow in action, dull.
Table 11
Embodiment 15 prepares Docetaxel albumin nanometer rice grain by high pressure homogenize effect
500 milligrams of Docetaxels are dissolved in 7.0 milliliters of ethanol.1300 milligrams of Polyethylene Glycol are dissolved in 1.5 milliliters of dehydrated alcohol, heat after complete melting 45 ℃ of oil baths, and paclitaxel solution is added wherein, and magnetic agitation is until its complete mix homogeneously, and rotary evaporation is removed after ethanol, cooling rapidly under intense agitation.After vacuum drying spends the night, solid dispersion is added in 90 milliliters of human serum albumin solutions (4.5%w/v).Mixture, is then transferred in high pressure homogenizer to form thick breast through high speed disperser premix 1 minute.Be emulsified in 9000-40,000 pound/inch
2condition under carry out, by Emulsion repetitive cycling at least 5 times.The system obtaining has denseer opalescence, and the general diameter of polyenic taxusol nano granule obtaining is in 135-200 nanometer.Result as shown in Figure 7.
Protein nano granule suspension is further lyophilizing 48 hours in the situation that not adding any cryoprotective agent.The powder obtaining can be easy to reconstitute protein nano granule suspension by adding sterilized water or normal saline.Roughly the same before the size of granule and lyophilizing after reconstruct.
Due to taxone dissolubility in aqueous medium very low (< 1 μ g/ml), it is negligible that therefore the free drug in aqueous medium is compared (> 2mg/ml) with the medication amount that is written into carrier.By centrifuging and taking supernatant liquid filtering, measure the method for subsequent filtrate Chinese medicine content and just can calculate the medication amount being written in carrier.
Precision takes a certain amount of albumin nanometer formulation (by embodiment of the present invention preparation) freeze-dried powder, and distilled water redissolves and is settled to scale, and jolting mixes.Destroy and be diluted to finite concentration with methanol, measure the content of preparation of Chinese medicine, distinguish computational envelope rate and drug loading by following formula (1) and (2).
Result shows, records through HPLC, and the drug loading of paclitaxel albumin nanometer formulation lyophilized powder is (9.67 ± 0.67) %, and envelop rate is (94.02 ± 6.4) %.The clinical application amount of paclitaxel is larger, and the paclitaxel albumin nanometer formulation that we prepare by the method has higher drug loading and envelop rate, can reduce administration volume, reduces the albuminous application of adjuvant, has good industrial prospect.
Embodiment 17
Inventor carries out single factor comparison (in table listed difference to different water-solubility carriers, protein substance respectively with reference to the method for embodiment 2, all the other are all identical with embodiment 2), the protein nano granule of preparation after testing mean diameter in table 13, table 14.Meanwhile, DSC detects and all shows that medicine is present in protein nano granular preparation with the form of amorphous or solid solution.
Table 13
Table 14
Claims (12)
1. wrap up a protein nano granule for taxone, it is characterized in that the material that the formula of this protein nano granule contains following percentage by weight:
0.1～10% taxone, 0.1～40% water-solubility carrier material, 50～90% protein substances;
Described protein substance is can be by the following material of sulfydryl and/or disulfide bond crosslinking: natural existence or synthetic protein, synthetic protein polymer or their mixture;
This protein nano granule prepares by following method:
A. taxone and water-solubility carrier material are made to the water-solubility carrier solid dispersion that contains taxone, if adopt solvent-free method not introduce any organic solvent while preparing solid dispersion, there is the method for solvent not introduce any other organic solvents except ethanol if adopt;
B. the solid dispersion of gained is added in the aqueous medium containing protein substance, mix homogeneously, mixture has obtained wrapping up the suspension of the protein nano granule of taxone through shear conditions processing;
C. suspension is dried or is first dried again through aseptic filtration, make solid preparation, semi-solid preparation or the gas preparation of the protein nano granule that has wrapped up taxone by required dosage form;
Or
Step b is obtained to suspension directly as liquid preparation or be further prepared into the liquid preparation of other types or by dry suspension or first redissolve and make liquid preparation again after aseptic filtration is dry again.
2. protein nano granule according to claim 1, is characterized in that taxone is selected from one or more in following material: paclitaxel, Docetaxel.
3. protein nano granule according to claim 1, is characterized in that described water-solubility carrier material is selected from one or more in following material: Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, polyethylene oxide, mixed aliphatic ester, mannitol, carbamide, sodium alginate, HPMC, polyacrylic resin, gelatin, sodium carboxymethyl cellulose.
4. protein nano granule according to claim 1, is characterized in that described naturally occurring protein is selected from one or more in following material: albumin, immunoglobulin, casein, lipoprotein, hemoglobin, lysozyme, α-2-macroglobulin, fibronectin, glass connect element, Fibrinogen, lipase; Described synthetic protein polymer is selected from one or more in the following material that adopts free sulfhydryl groups and/or disulfide group modification: poly-ethyl oxazoline, polyacrylamide, polyvinylpyrrolidone, polyglycols, PGA, polycaprolactone or its copolymer, synthetic polyamino acid.
5. the preparation method of protein nano granule as claimed in claim 1, is characterized in that the method comprises the following steps:
A. taxone and water-solubility carrier material are made to the water-solubility carrier solid dispersion that contains taxone, if adopt solvent-free method not introduce any organic solvent while preparing solid dispersion, there is the method for solvent not introduce any other organic solvents except ethanol if adopt;
B. the solid dispersion of gained is added in the aqueous medium containing protein substance, mix homogeneously, mixture has obtained wrapping up the suspension of the protein nano granule of taxone through shear conditions processing;
C. suspension is dried or is first dried again through aseptic filtration, make solid preparation, semi-solid preparation or the gas preparation of the protein nano granule that has wrapped up taxone by required dosage form;
Or
Step b is obtained to suspension directly as liquid preparation or be further prepared into the liquid preparation of other types or by dry suspension or first redissolve and make liquid preparation again after aseptic filtration is dry again.
6. preparation method according to claim 5, it is characterized in that described aqueous medium is selected from water for injection, pure water, mannitol solution, aqueous phosphatic, dextran solution, D/W, sodium-chloride water solution, Freamine Ⅲ, vitamin solution, or their any two or more mixture.
7. preparation method according to claim 5, is characterized in that the method for water-solubility carrier solid dispersion that preparation contains taxone is fusion method, solvent method, solvent-fusion method, solvent-atomizing freeze drying method, polishing or Double helix squeezing and pressing method; If adopt solvent-free method not introduce any organic solvent in these methods, there is the method for solvent not introduce any other organic solvents except ethanol if adopt; Described shear conditions refers to that application possesses the equipment of high pressure and high shearforce simultaneously, makes mixture reach efficient mixing, pulverizing, dispersion and emulsifying object; Wherein, high pressure refers to that pressure limit is at 5000 to 30000 pounds/inch
2.
8. preparation method according to claim 7, is characterized in that the method for water-solubility carrier solid dispersion that preparation contains taxone is solvent-fusion method.
9. preparation method according to claim 7, is characterized in that high pressure refers to that pressure limit is at 6000～25000 pounds/inch
2.
10. preparation method according to claim 5, the mean diameter that it is characterized in that this protein nano granule is 20～1000nm
11. preparation methoies according to claim 10, the mean diameter that it is characterized in that this protein nano granule is 20～200nm.
12. preparation methoies according to claim 5, is characterized in that drying means adopts lyophilization or spraying to be dried; Aseptic filtration adopts 0.22 μ m filter to filter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110299784.9A CN102327230B (en) | 2011-09-30 | 2011-09-30 | Protein nanometer granules wrapped with taxane medicaments and preparation method for nanometer granules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110299784.9A CN102327230B (en) | 2011-09-30 | 2011-09-30 | Protein nanometer granules wrapped with taxane medicaments and preparation method for nanometer granules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102327230A CN102327230A (en) | 2012-01-25 |
| CN102327230B true CN102327230B (en) | 2014-05-21 |
Family
ID=45479365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110299784.9A Expired - Fee Related CN102327230B (en) | 2011-09-30 | 2011-09-30 | Protein nanometer granules wrapped with taxane medicaments and preparation method for nanometer granules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102327230B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688200B (en) * | 2012-05-09 | 2014-03-26 | 广州帝奇医药技术有限公司 | Plant anti-cancer targeting nano-preparation, and preparation method thereof |
| CN104758942A (en) * | 2014-01-02 | 2015-07-08 | 国家纳米科学中心 | Protein-based pharmacological active substance composition, and preparation method and applications thereof |
| CN104667289B (en) * | 2014-01-28 | 2018-08-14 | 暨南大学 | A kind of antineoplastic drug carrier and its application method |
| CN104208030A (en) * | 2014-08-01 | 2014-12-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Albumin-combined taxol long-circulation nano-particle freeze-dried preparation |
| CN105412024B (en) * | 2015-12-14 | 2018-03-30 | 广州帝奇医药技术有限公司 | Target hydrophobic anticancer drug nanometer formulation and preparation method thereof |
| ES2925656T3 (en) * | 2016-04-29 | 2022-10-19 | Rousselot B V | Protein-based excipient for active pharmaceutical ingredients |
| CN109562073B (en) * | 2016-09-29 | 2021-11-09 | 四川科伦药物研究院有限公司 | Albumin pharmaceutical composition and preparation method thereof |
| CN107412783B (en) * | 2017-04-28 | 2020-09-22 | 中国人民解放军军事医学科学院毒物药物研究所 | Preparation method of protein particles coated with water-insoluble medicine |
| CN107485718B (en) * | 2017-08-25 | 2020-05-22 | 莎穆(上海)生物科技有限公司 | Combined nano preparation of camptothecin and taxus medicine and preparation thereof |
| CN109464420B (en) * | 2018-10-08 | 2021-06-29 | 中山大学 | Egg white-based food bionic nano drug delivery system and preparation method and application thereof |
| CN111116614B (en) * | 2018-11-01 | 2022-12-13 | 复旦大学 | Covalent linker of immune regulatory factor and taxane, albumin nano preparation thereof and preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385857A (en) * | 2008-10-21 | 2009-03-18 | 中国药科大学 | Novel nano preparation with stable protein and preparation method and use thereof |
| CN102133190A (en) * | 2011-03-16 | 2011-07-27 | 中国药科大学 | Transferrin nanoparticles and preparation method and application thereof |
-
2011
- 2011-09-30 CN CN201110299784.9A patent/CN102327230B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385857A (en) * | 2008-10-21 | 2009-03-18 | 中国药科大学 | Novel nano preparation with stable protein and preparation method and use thereof |
| CN102133190A (en) * | 2011-03-16 | 2011-07-27 | 中国药科大学 | Transferrin nanoparticles and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| Mohsen Jahanshahi等.Protein nanoparticle:A unique system as drug delivery vehicles.《African Journal of Biotechnology》.2008,第7卷(第25期),4926-4934. |
| Protein nanoparticle:A unique system as drug delivery vehicles;Mohsen Jahanshahi等;《African Journal of Biotechnology》;20081229;第7卷(第25期);4926-4934 * |
| 白蛋白作为注射用难溶性药物载体的研究进展;陈辰等;《中国医药工业杂志》;20101231;第41卷(第1期);51-54 * |
| 陈辰等.白蛋白作为注射用难溶性药物载体的研究进展.《中国医药工业杂志》.2010,第41卷(第1期),51-54. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102327230A (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102327230B (en) | Protein nanometer granules wrapped with taxane medicaments and preparation method for nanometer granules | |
| KR100904931B1 (en) | Nanoparticles and Method for the Preparation Thereof | |
| CN102357077B (en) | Protein nanometer particle for wrapping slightly soluble medicines and preparation method thereof | |
| Banerjee et al. | Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors | |
| Zhang et al. | Improving anti-tumor activity of curcumin by polymeric micelles in thermosensitive hydrogel system in colorectal peritoneal carcinomatosis model | |
| JP2014518862A (en) | Polymer nanoparticles for drug delivery | |
| CN101984958A (en) | Nanoscale albendazole micropowder and preparation method thereof | |
| CN102688200A (en) | Plant anti-cancer targeting nano-preparation, and preparation method thereof | |
| CN102357076B (en) | Preparation method of protein nanoparticles coating insoluble drug | |
| Yang et al. | Polydopamine-modified ROS-responsive prodrug nanoplatform with enhanced stability for precise treatment of breast cancer | |
| JP6738500B2 (en) | Protein particles containing poorly water-soluble drug and method for preparing the same | |
| Wu et al. | Hydrogen-bonded supramolecular polymer micelles with pH/photothermal-responsive carmofur release and combined chemo-photothermal therapy | |
| CN109078184B (en) | Loaded double-drug nanoparticle and preparation method and application thereof | |
| CN106983719A (en) | A kind of docetaxel polymer nano micelle injection, its preparation method and its application in tumor is prepared | |
| CN111202719A (en) | Active natural product nano drug delivery system and preparation method and application thereof | |
| CN109674741B (en) | Pharmaceutical carrier and process for preparing the same | |
| Ghaemi et al. | Targeted Nano-Delivery of Flutamide with polymeric and lipid nanoparticles | |
| Jawahar et al. | Development and characterization of PLGA-nanoparticles containing carvedilol | |
| CN111135314A (en) | Nano-composite for early diagnosis and treatment of gastric cancer and preparation method thereof | |
| KR101180181B1 (en) | Nanoparticles and Method for the Preparation Thereof | |
| Cao et al. | Combretastatin A4-loaded Poly (Lactic-co-glycolic Acid)/Soybean Lecithin Nanoparticles with Enhanced Drug Dissolution Rate and Antiproliferation Activity | |
| CN110237050A (en) | A kind of Combretastatin nanoparticle and preparation method thereof | |
| Zhou et al. | β-Glycosidase sensitive oral nanoparticles for combined photothermal and chemo treatment of colorectal cancer | |
| CN115227683B (en) | Inhalation type composite microsphere for treating pulmonary diseases and preparation method thereof | |
| KR101329573B1 (en) | Rebombinant Human Gelatin Conjugate and Use Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140521 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |